Muted Q1 For Aurobindo But Outlook Firm; Don’t Expect ‘Exotic’ M&A

Aurobindo Pharma reported a subdued Q1 but investors remained upbeat on the firm’s prospects as it transitions to a larger complex generics play. The company also emphasized its “disciplined” M&A approach; it has no interest in chasing “exotic” deals.